Hydrogen sulfide signalling in neurodegenerative diseases
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.16170 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Sunil Jamuna Tripathi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Hydrogen Sulfide, Neurodegenerative Diseases, Signal Transduction. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
The gaseous neurotransmitter hydrogen sulfide (H 2 S) exerts neuroprotective efficacy in the brain via post‐translational modification of cysteine residues by sulfhydration, also known as persulfidation. This process is comparable in biological impact to phosphorylation and mediates a variety of signalling events. Unlike conventional neurotransmitters, H 2 S cannot be stored in vesicles due to its gaseous nature. Instead, it is either locally synthesized or released from endogenous stores. Sulfhydration affords both specific and general neuroprotective effects and is critically diminished in several neurodegenerative disorders. Conversely, some forms of neurodegenerative disease are linked to excessive cellular H 2 S. Here, we review the signalling roles of H 2 S across the spectrum of neurodegenerative diseases, including Huntington's disease, Parkinson's disease, Alzheimer's disease, Down syndrome, traumatic brain injury, the ataxias, and amyotrophic lateral sclerosis, as well as neurodegeneration generally associated with ageing. LINKED ARTICLES This article is part of a themed issue Recent Innovations in Targeting Redox Biology for Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.1/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA.
- Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, Ohio, USA.
- School of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
ORCID-Profile: Bindu D Paul
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- NIDA NIH HHS
- BLRD VA
- Case Western Reserve University Rebecca E. Barchas, M.D., Endowed Professorship in Translational Psychiatry
- Catalyst Award, Johns Hopkins University
- Department of Veterans Affairs Merit Award
- Elizabeth Ring Mather & William Gwinn Mather Fund
Zitieren
APA
Tripathi, S. J., Chakraborty, S., Miller, E., Pieper, A. A., & Paul, B. D. (2026). Hydrogen sulfide signalling in neurodegenerative diseases. British Journal of Pharmacology. https://doi.org/10.1111/bph.16170
Vancouver
Tripathi SJ, Chakraborty S, Miller E, Pieper AA, Paul BD. Hydrogen sulfide signalling in neurodegenerative diseases. British Journal of Pharmacology. 2026. doi:10.1111/bph.16170
BibTeX
@article{Tripathi2026,
author = {Tripathi, Sunil Jamuna and Chakraborty, Suwarna and Miller, Emiko and Pieper, Andrew A and Paul, Bindu D},
title = {Hydrogen sulfide signalling in neurodegenerative diseases},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.16170}
}
EUVIMED